Market open

uniQure/$QURE

13:30

15:10

16:45

18:25

20:00

1D1W1MYTD1Y5YMAX

About uniQure

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Ticker

$QURE

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Amsterdam, Netherlands

Employees

209

ISIN

NL0010696654

Website

www.uniqure.com

uniQure Metrics

BasicAdvanced

$692M

-

-$4.37

-

Price and volume

Market cap

$692M

52-week high

$19.18

52-week low

$3.73

Average daily volume

2.3M

Financial strength

Current ratio

11.992

Quick ratio

11.334

Long term debt to equity

1,511.483

Total debt to equity

1,522.46

Interest coverage (TTM)

-2.62%

Management effectiveness

Return on assets (TTM)

-15.19%

Return on equity (TTM)

-241.16%

Valuation

Price to revenue (TTM)

31.204

Price to book

19.94

Price to tangible book (TTM)

-10.9

Growth

Revenue change (TTM)

6.30%

Earnings per share change (TTM)

-29.55%

3-year revenue growth (CAGR)

-66.25%

3-year earnings per share growth (CAGR)

-14.09%

What the Analysts think about uniQure

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for uniQure stock.

uniQure Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

uniQure Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

uniQure News

AllArticlesVideos

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

Seeking Alpha·6 days ago

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

GlobeNewsWire·6 days ago

uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data

Seeking Alpha·1 week ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $QURE

Capital at risk

Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for uniQure stock?

uniQure (QURE) has a market cap of $692M as of May 15, 2025.

What is the P/E ratio for uniQure stock?

The price to earnings (P/E) ratio for uniQure (QURE) stock is 0 as of May 15, 2025.

Does uniQure stock pay dividends?

No, uniQure (QURE) stock does not pay dividends to its shareholders as of May 15, 2025.

When is the next uniQure dividend payment date?

uniQure (QURE) stock does not pay dividends to its shareholders.

What is the beta indicator for uniQure?

uniQure (QURE) does not currently have a Beta indicator.